{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T04:47:37Z","timestamp":1782622057453,"version":"3.54.5"},"reference-count":34,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The aim of this study was to develop and validate a HPLC stability indicating assay for evaluating the calcium levofolinate long-term stability at standardized rounded doses in polyolefin (POF) infusion bags and in polypropylene syringes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Diluted calcium levofolinate infusion solutions were aseptically prepared by further dilution of calcium levofolinate stock solution with dextrose 5% in POF infusion bags (268\u2005mL) at banded doses of 160\u2005mg, 300\u2005mg, and 400\u2005mg or in polypropylene syringes (10\u2005mL) at 25\u2005mg banded dose. The POF bags and the syringes were stored under refrigeration (5\u00b0C\u2009\u00b1\u20093\u00b0C) in the dark. Microbiological, physical and chemical stabilities were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The long-term stability of calcium levofolinate at banded doses 160\u2005mg, 300\u2005mg, 400\u2005mg in POF infusion bags was confirmed for respectively 15 weeks, 18 weeks and 19 weeks. For syringes, for a 25\u2005mg banded dose, this long\u2014term stability was confirmed for 20 weeks. Microbiological tests performed were negative.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A simple, accurate and stability-indicating HPLC method was developed to determine calcium levofolinate concentrations in dose-banding conditions associated with color variation investigation. This study supports a centralized production of calcium levofolinate in accordance with the studied conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251409124","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:49:27Z","timestamp":1767984567000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["A fully validated HPLC-UV detection method associated with color variation control for the evaluation of the long term stability of calcium levofolinate solutions in polyolefin infusion bags and in polypropylene syringes in dose banding conditions"],"prefix":"10.1177","author":[{"given":"Claire","family":"Andre","sequence":"first","affiliation":[{"name":"UFR Sant\u00e9"},{"name":"Inserm, UMR 1322, \u00ab LINC-Neurosciences Int\u00e9grative et Cliniques \u00bb, P\u00f4le Chimie, Analytique Bio analytique et Physique (PCABP), Univ Franche-Comt\u00e9, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydie","family":"Lethier","sequence":"additional","affiliation":[{"name":"UFR Sant\u00e9"},{"name":"Inserm, UMR 1322, \u00ab LINC-Neurosciences Int\u00e9grative et Cliniques \u00bb, P\u00f4le Chimie, Analytique Bio analytique et Physique (PCABP), Univ Franche-Comt\u00e9, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4571-7780","authenticated-orcid":false,"given":"Yves Claude","family":"Guillaume","sequence":"additional","affiliation":[{"name":"UFR Sant\u00e9"},{"name":"Inserm, UMR 1322, \u00ab LINC-Neurosciences Int\u00e9grative et Cliniques \u00bb, P\u00f4le Chimie, Analytique Bio analytique et Physique (PCABP), Univ Franche-Comt\u00e9, Besan\u00e7on, France"},{"name":"P\u00f4le Pharmaceutique, CHU Jean-Minjoz, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2002.10.001"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02440861"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1999.tb00043.x"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1074"},{"key":"e_1_3_3_6_2","first-page":"457","article-title":"Phase II study of a weekly 24-hour infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancer","volume":"24","author":"Hartung G","year":"2001","unstructured":"Hartung G, Hofheinz RD, Wein A, et al. Phase II study of a weekly 24-hour infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancer. Onkologie 2001; 24: 457\u2013462.","journal-title":"Onkologie"},{"key":"e_1_3_3_7_2","first-page":"449","article-title":"Second -line treatment of advanced colorectal cancer with a weekly simultaneous 24-hour infusion of 5-fluorouracil and sodium-folinate: a multicentre phase II trial","volume":"27","author":"Kuhfahl J","year":"2004","unstructured":"Kuhfahl J, Steinbrecher C, Wagner T, et al. Second -line treatment of advanced colorectal cancer with a weekly simultaneous 24-hour infusion of 5-fluorouracil and sodium-folinate: a multicentre phase II trial. Onkologie 2004; 27: 449\u2013454.","journal-title":"Onkologie"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.1.136"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02034-1"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.357"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0048"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/58.18.1760"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/PTS.0000000000001047"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155207080118"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220918025"},{"key":"e_1_3_3_16_2","first-page":"301","article-title":"Stability of calcium levofolinate (TEVA) in concentrate after re-use and in dilute infusions in 0.9% NaCl in polyethylene bags","volume":"70","author":"Karbownik A","year":"2013","unstructured":"Karbownik A, Szalek E, Urjasz H, et al. Stability of calcium levofolinate (TEVA) in concentrate after re-use and in dilute infusions in 0.9% NaCl in polyethylene bags. Acta Pol Pharm 2013; 70: 301\u2013307.","journal-title":"Acta Pol Pharm"},{"key":"e_1_3_3_17_2","volume-title":"Standard practice for computing the color of objects by using the CIE system","author":"ASTM","year":"2012","unstructured":"ASTM. Standard practice for computing the color of objects by using the CIE system. West Conshohocken, PA: ASTM E308-08, 2012."},{"key":"e_1_3_3_18_2","doi-asserted-by":"crossref","unstructured":"Choudhury AKR. Visual measures of colour. In: Principles of colour and appearance measurement. Cambridge UK: Elsevier 2015 pp.1\u201325.","DOI":"10.1533\/9781782423881.1"},{"key":"e_1_3_3_19_2","doi-asserted-by":"crossref","unstructured":"Choudhury AKR. Using instruments to quantify colour. In: Principles of colour and appearance measurement. Cambridge UK: Elsevier 2014 pp.270\u2013317.","DOI":"10.1533\/9780857099242.270"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12937-016-0149-x"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharma.2011.07.002"},{"key":"e_1_3_3_22_2","unstructured":"SFPC (French Society of Clinical Pharmacy) and GERPAC (Evaluation and Research Group on Protection in Controlled Atmospher). SFPC GERPAC Methodological guidelines for stability studies of hospital pharmaceutical pre- parations Part I : Liquid preparations. http:\/\/www.gerpac.eu\/IMG\/pdf\/ guide-stabilite-anglais.pdf. Accessed March 2 2019."},{"key":"e_1_3_3_23_2","first-page":"360","volume-title":"European pharmacopoeia","year":"2019","unstructured":"Pharmaceutical technical procedures, 2.9.19: particulate contamination: sub-visible particles. In: European pharmacopoeia. 9th ed. Strasbourg, France: European Directorate for the Quality of Medicines and Health Care, 2019, pp.360\u2013362.","edition":"9"},{"key":"e_1_3_3_24_2","unstructured":"International Conference for Harmonisation. Harmonise tripartite guideline-stability testing of new drug substances and products Q1A(R2) step 4. www.ich.orghttps:\/\/www. ich.org\/fileadmin\/ Public-Web-Site \/ ICH-Products \/Guidelines\/Quality\/ Q1A-R2\/Step4\/Q1AR2-Guideline.pdf. Published 2003. Accessed March 2 2019."},{"key":"e_1_3_3_25_2","unstructured":"General methods. 2.6 Biological methods. 2.6.1 Sterility 01\/2005: 20601 European Pharmacopoeia 5th edition 2005; pp.153\u2013157."},{"key":"e_1_3_3_26_2","first-page":"197","volume-title":"European pharmacopoeia","year":"2019","unstructured":"Biological tests, 2.6.1: sterility. In: European pharmacopoeia. 9thed. Strasbourg, France: European Directorate for the Quality of Medicines and Heath Care, 2019, pp.197\u2013207.","edition":"9"},{"key":"e_1_3_3_27_2","first-page":"101","article-title":"Validation des proc\u00e9dures analytiques quantitatives, Harmonisation des d\u00e9marches","volume":"13","author":"Hubert P","year":"2003","unstructured":"Hubert P, Boulanger B, Nguyen-Huu JJ, et al. Validation des proc\u00e9dures analytiques quantitatives, Harmonisation des d\u00e9marches. STP Pharma Pratiques 2003; 13: 101\u2013138.","journal-title":"STP Pharma Pratiques"},{"key":"e_1_3_3_28_2","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q2(R2) Validation of Analytical Procedures (2023). Accessed November 20\/2024. https:\/\/database.ich.org\/sites\/default\/files\/ICH-Q2%28R2%29-Guideline-2023-1130.pdf"},{"key":"e_1_3_3_29_2","first-page":"480","article-title":"Method validation and robustness","volume":"24","author":"Swartz ME","year":"2006","unstructured":"Swartz ME, Krull IS. Method validation and robustness. LC-GC 2006; 24: 480\u2013490.","journal-title":"LC-GC"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552251338763"},{"key":"e_1_3_3_31_2","first-page":"81","volume-title":"European pharmacopoeia","year":"2019","unstructured":"Physical and physicochemical methods, 2.2.46: chromatographic separation techniques. In: European pharmacopoeia. 9th ed. Strasbourg, France: European Directorate for the Quality of Medicines and Health Care, 2019, pp.81\u201388.","edition":"9"},{"key":"e_1_3_3_32_2","first-page":"22","article-title":"A well written analytical procedure for regulated HPLC testing","volume":"1","author":"Dong MW","year":"2024","unstructured":"Dong MW. A well written analytical procedure for regulated HPLC testing. LC-GC 2024; 1: 22\u201329.","journal-title":"LC-GC"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.procbio.2019.08.013"},{"key":"e_1_3_3_34_2","unstructured":"Monography 2.2.2. Degree of Coloration of Liquids: European Pharmacopoeia 10.5. (2021)"},{"key":"e_1_3_3_35_2","unstructured":"United States Pharmacopeia. USP <1061 > Color : Instrumental measurement USPNF 2021 Issue 2. (2021)."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251409124","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251409124","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251409124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:32:05Z","timestamp":1777689125000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251409124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":34,"alternative-id":["10.1177\/10781552251409124"],"URL":"https:\/\/doi.org\/10.1177\/10781552251409124","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"article-number":"10781552251409124"}}